(Reuters) – The U.S. Food and Drug Administration has approved Apellis Pharmaceuticals Inc’s drug to treat an advanced eye disorder that is one of the leading causes of blindness globally, the company said on Friday.
The drug, brand name Syfovre, slowed down the progression of the eye disease geographic atrophy (GA), becoming the first and only FDA-approved treatment for the indication.
Apellis said the drug is expected to be available by the beginning of March through specialty distributors and specialty pharmacies in the United States.
(Reporting by Aditya Samal and Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber and Krishna Chandra Eluri)
